Hyperbaric oxygen for Multiple Myeloma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Multiple MyelomaHyperbaric oxygen - Drug
Eligibility
18 - 75
All Sexes
What conditions do you have?
Select

Study Summary

This trial is for subjects with multiple myeloma who are eligible for high-dose therapy and autologous stem cell transplantation.

Eligible Conditions
  • Multiple Myeloma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: 100 days

100 days
Therapeutic procedure
Time to neutrophil recovery
24 hours
Number of participants with a treatment-limiting toxicity

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Experimental Arm:single
1 of 1

Experimental Treatment

15 Total Participants · 1 Treatment Group

Primary Treatment: Hyperbaric oxygen · No Placebo Group · Phase < 1

Experimental Arm:single
Drug
Experimental Group · 1 Intervention: Hyperbaric oxygen · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Hyperbaric oxygen
2020
Completed Phase 2
~220

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 100 days

Who is running the clinical trial?

University of RochesterLead Sponsor
791 Previous Clinical Trials
501,734 Total Patients Enrolled
11 Trials studying Multiple Myeloma
311 Patients Enrolled for Multiple Myeloma
Omar Aljitawi, MMBSPrincipal InvestigatorUniversity of Rochester

Eligibility Criteria

Age 18 - 75 · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: